The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Goyal, Jatinder ^a   Nuhn, Philipp ^a,b   Huang, Peng ^a   Tyagi, Prachi ^a   Oh, Daniel ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Clinical trial; Docetaxel; Metastatic castration resistant prostate cancer; Overall survival; Prostate cancer

Indexed keywords

ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; KETOCONAZOLE; MITOXANTRONE; MOCETINOSTAT; PLACEBO; PREDNISONE; SAMARIUM 153; SILTUXIMAB; SULINDAC SULFONE; VADIMEZAN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; RADIOSENSITIZING AGENT; TAXOID;

ADULT; AGE; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CAREGIVER; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT CARE; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GERMANY; METASTASIS; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PATIENT COMPLIANCE; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; UNITED STATES;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GERMANY; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PATIENT COMPLIANCE; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TAXOIDS; UNITED STATES;

MLCS; MLOWN;

EID: 84876454014     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11286.x     Document Type: Article

References (39)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 ; 351 : 1502-12
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 ; 351 : 1513-20
3. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 ; 364 : 1995-2005
4. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010 ; 376 : 1147-54
5. Sonpavde G, Attard G, Bellmunt J et al. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 2011 ; 60 : 270-8
6. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011 ; 59 : 572-83
7. Beltran H, Beer TM, Carducci MA et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 2011 ; 60 : 279-90
8. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 ; 363 : 411-22
9. Antonarakis ES, Armstrong AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 ; 14 : 206-18
10. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011 ; 364 : 2055-8
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646-74
12. Joniau S, Abrahamsson PA, Bellmunt J et al. Current vaccination strategies for prostate cancer. Eur Urol 2012 ; 61 : 290-306
13. Tanai C, Nokihara H, Yamamoto S et al. Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. Br J Cancer 2009 ; 100 : 1037-42
14. Lara PN Jr, Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001 ; 19 : 1728-33
15. Corrie P, Shaw J, Harris R. Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study. BMJ 2003 ; 327 : 320-1
16. Go RS, Frisby KA, Lee JA et al. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 2006 ; 106 : 426-33
17. Tanai C, Nakajima TE, Nagashima K et al. Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial. J Oncol Pract 2011 ; 7 : 148-53
18. Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 2000 ; 82 : 1783-8
19. Albrecht TL, Eggly SS, Gleason ME et al. Influence of clinical communication on patients ' decision making on participation in clinical trials. J Clin Oncol 2008 ; 26 : 2666-73
20. Wright JR, Whelan TJ, Schiff S et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol 2004 ; 22 : 4312-18
21. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a 'trial effect'. J Clin Epidemiol 2001 ; 54 : 217-24
22. Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2012 ; 30 : 1534-40
23. Sinibaldi VJ, Elza-Brown K, Schmidt J et al. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol 2006 ; 29 : 395-8
24. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgenin-dependent prostate cancer. J Clin Oncol 2003 ; 21 : 123-8
25. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001 ; 19 : 2509-16
26. Jameson MB, Thompson PI, Baguley BC et al. Phase I/II Trials Committee of Cancer Research UK. Clinical aspects of a phase I trial of 5,6- dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003 ; 88 : 1844-50
27. Lin J, Sinibaldi VJ, Carducci MA et al. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol 2011 ; 29 : 670-5
28. Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2009 ; Abstract LBA150
29. Hudes GR, Tagawa S, Whang Y et al. A phase I study of CNTO 328, an antiinterleukin (IL)-6 monoclonal antibody combined with docetaxel (T) in subjects with metastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2009 ; Abstract 164
30. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 ; 26 : 1148-59
31. Dinse GE, Lagakos SW. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 1982 ; 38 : 921-32
32. Karrison T. Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Stat Med 1996 ; 15 : 171-82
33. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 ; 45 : 228-47
34. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004 ; 363 : 263-70
35. Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986 ; 314 : 1600-6
36. Davis S, Wright PW, Schulman SF et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985 ; 56 : 1710-18
37. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003 ; 21 : 1232-7
38. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010 ; 16 : 203-11
39. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007 ; 13 : 6396-403